Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | ACLY | P53396 | 8/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662607 | 0.95 | ACACB (0.45) | ACACBACACAPPARGPPARAACLY | |
| SCHEMBL4661274 | 0.88 | ACACB (0.43) | ACACBACACAPPARGPPARAACLY | |
| SCHEMBL4661240 | 0.85 | HTR1A (0.39) | ACACBACACAPPARGPPARAACLY | |
| SCHEMBL7615412 | 0.84 | HDAC3 (0.49) | PPARGPPARAACLYL3MBTL1 | |
| SCHEMBL7620776 | 0.84 | HDAC3 (0.49) | PPARGPPARAACLYL3MBTL1 | |
| SCHEMBL682183 | 0.84 | HDAC3 (0.49) | PPARGPPARAACLYL3MBTL1 | |
| SCHEMBL9055670 | 0.81 | ACACB (0.66) | ACACBACACAACLY | |
| SCHEMBL4659866 | 0.80 | ACACB (0.39) | ACACBACACAACLY | |
| SCHEMBL4659864 | 0.80 | HDAC3 (0.41) | PPARGPPARAACLYTRPA1TRPV1 | |
| SCHEMBL27630618 | 0.79 | PPARA (0.46) | PPARGPPARAACLYTRPA1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261933-A1 | METHOD FOR PREPARING CARBOXYLIC ACID COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-10-14 | — | — | US | claimed |
| EP-1627866-B1 | CARBOXYLIC ACID COMPOUND AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-2003112-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID COMPOUND | Kowa Company, Ltd. (JP) | 2008-12-17 | — | — | EP | claimed |
| US-7109242-B2 | Carboxylic compound and medicine comprising the same | KOWA COMPANY, LTD. (JP) | 2006-09-19 | — | — | US | claimed |
| EP-1627866-A1 | CARBOXYLIC ACID COMPOUND AND MEDICINE CONTAINING THE SAME | Kowa Company Ltd. (JP) | 2006-02-22 | — | — | EP | claimed |
| US-20050009909-A1 | Carboxylic compound and medicine comprising the same | KOWA COMPANY, LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| US-20100261933-A1 | METHOD FOR PREPARING CARBOXYLIC ACID COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261933-A1 | METHOD FOR PREPARING CARBOXYLIC ACID COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261933-A1 | METHOD FOR PREPARING CARBOXYLIC ACID COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261933-A1 | METHOD FOR PREPARING CARBOXYLIC ACID COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-1627866-B1 | CARBOXYLIC ACID COMPOUND AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2008-12-24 | — | — | EP | disclosed |
| EP-2003112-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID COMPOUND | Kowa Company, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| EP-2003112-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID COMPOUND | Kowa Company, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| EP-2003112-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID COMPOUND | Kowa Company, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007114223-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID COMPOUND | KOWA COMPANY, LTD. (JP) | 2007-10-11 | — | — | WO | disclosed |
| US-7109242-B2 | Carboxylic compound and medicine comprising the same | KOWA COMPANY, LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-1627866-A1 | CARBOXYLIC ACID COMPOUND AND MEDICINE CONTAINING THE SAME | Kowa Company Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20050009909-A1 | Carboxylic compound and medicine comprising the same | KOWA COMPANY, LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009909-A1 | Carboxylic compound and medicine comprising the same | CPT1A, GPR119, PNLIP | ACACB 117/4885ACACA 54/4885PPARG 65/4885 |
| US-20100261933-A1 | METHOD FOR PREPARING CARBOXYLIC ACID COMPOUND | HCAR1, HAO1, HCAR2 | ACACB 233/4885ACACA 84/4885PPARG 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.